No Data
Craig-Hallum Releases a Buy Rating on Diamedica Therapeutics (DMAC)
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Largest Shareholders Are Individual Investors With 50% Ownership, Insiders Own 39%
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
Express News | DiaMedica Therapeutics Files For Resale Of Up To 4.7M Common Shares By The Selling Shareholders
Express News | DiaMedica Therapeutics Inc Files for Resale of up to 4.7 Mln Common Shares by the Selling Shareholders - SEC Filing
Express News | DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement